Truist Securities Upgrades Evolent Health to Buy, Maintains Price Target to $6
Benzinga Newsdesk 14 hours ago
Analyst RatingsNewsUpgradesPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Truist Securities analyst Jailendra Singh upgrades Evolent Health (NYSE:EVH) from Hold to Buy and maintains the price target from $6 to $6.
Truist Securities analyst Jailendra Singh upgrades Evolent Health (NYSE:EVH) from Hold to Buy and maintains the price target from $6 to $6.
